Table 2. Current and emerging approaches... | American Society of Hematology

Table 2.

Current and emerging approaches to enhance allogeneic HCT for nonmalignant disease

	Current approaches	Emerging approaches
Conditioning regimens	Use of traditional agents in combinations that limit toxicities	Antibody-based conditioning (anti-CD117, anti-CD45)
Graft sources	Unmanipulated BM, PBSC, or UCB	Ex vivo UCB expansion (nicotinamide)
GVHD prophylaxis	CNI-based prophylactic regimens Addition of ATG PTCy-based prophylactic regimens Traditional T-cell depletion	Wider adoption of PTCy-based regimens Novel targeted agents (CD24, CD26, α4β7 integrin, JAK1 or JAK 1/2, T-cell costimulation) Novel depletion approaches (CD3⁺/CD19⁺, TCRαβ⁺, CD45RA⁺) Infusion of ex vivo expanded or highly purified regulatory T-cells after CD34⁺ selected HCT

	Current approaches	Emerging approaches
Conditioning regimens	Use of traditional agents in combinations that limit toxicities	Antibody-based conditioning (anti-CD117, anti-CD45)
Graft sources	Unmanipulated BM, PBSC, or UCB	Ex vivo UCB expansion (nicotinamide)
GVHD prophylaxis	CNI-based prophylactic regimens Addition of ATG PTCy-based prophylactic regimens Traditional T-cell depletion	Wider adoption of PTCy-based regimens Novel targeted agents (CD24, CD26, α4β7 integrin, JAK1 or JAK 1/2, T-cell costimulation) Novel depletion approaches (CD3⁺/CD19⁺, TCRαβ⁺, CD45RA⁺) Infusion of ex vivo expanded or highly purified regulatory T-cells after CD34⁺ selected HCT

JAK, Janus kinase.